Cellectar Biosciences (CLRB)

Cellectar Biosciences Stock Analysis & Ratings

CLRB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.34 - $1.25
Previous Close$0.41
Average Volume (3M)149.93K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.0
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $0.34 and its highest was $1.25 in the past 12 months.
    What is Cellectar Biosciences’s market cap?
    Currently, no data Available
    What is Cellectar Biosciences’s price target?
    The average price target for Cellectar Biosciences is $5.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 1063.06% Increase from the current price of $0.43.
      What do analysts say about Cellectar Biosciences?
      Cellectar Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Cellectar Biosciences’s upcoming earnings report date?
        Cellectar Biosciences’s upcoming earnings report date is Aug 15, 2022 which is in 40 days.
          How were Cellectar Biosciences’s earnings last quarter?
          Cellectar Biosciences released its earnings results on May 10, 2022. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.005.
            Is Cellectar Biosciences overvalued?
            According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Cellectar Biosciences pay dividends?
              Cellectar Biosciences does not currently pay dividends.
              What is Cellectar Biosciences’s EPS estimate?
              Cellectar Biosciences’s EPS estimate is -$0.1.
                How many shares outstanding does Cellectar Biosciences have?
                Cellectar Biosciences has 61,101,250 shares outstanding.
                  What happened to Cellectar Biosciences’s price movement after its last earnings report?
                  Cellectar Biosciences reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -9.091%.
                    Which hedge fund is a major shareholder of Cellectar Biosciences?
                    Among the largest hedge funds holding Cellectar Biosciences’s share is Consonance Capital. It holds Cellectar Biosciences’s shares valued at N/A.


                      Cellectar Biosciences Stock Analysis

                      Smart Score
                      Not Ranked
                      Price Target
                      ▲(1063.06% Upside)
                      Moderate Buy
                      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cellectar Biosciences

                      Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.

                      Similar Stocks
                      Price & Change
                      GT Biopharma
                      OncoVista Innovative Therapies
                      Infinity Pharma
                      Catalyst Pharma
                      BioMarin Pharmaceutical

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis